Up 70%, Peregrine's Clinical Lemon Becomes Lemonade

Before you go, we thought you'd like these...
Before you go close icon

Since the company's clinical data mix-up in a non-small-cell lung cancer study of bavituximab, Peregrine investors have been anxiously waiting to see what, if any, life might remain for the drug in this potentially lucrative indication. Today, the company released interim findings from its investigation into the mishap, and, as one might expect to see from a company with its back against the wall, the findings were considered positive. However, as Brenton Flynn discusses in the following video, investor should approach this with a "once bitten, twice shy" mentality.

If you're an investor looking for huge long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

The article Up 70%, Peregrine's Clinical Lemon Becomes Lemonade originally appeared on Fool.com.

Brenton Flynn has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

People are Reading